Mithra’s Donesta phase 3 trial results, page-2

Exactly ! Mithra shares down 70% ytd.
They’re cash poor. The low take up of
Nextellis in USA being a big contributor
to their expectations along with Mayne
shareholders.The profit positive first year
outlook has come and gone. The $200m
revenue now appears Pie in the Sky for this
revolutionary Pill . Menopause market is
far less competitive and yet market is huge
and growing. Since Mithra is already at Phase
3 trials for FDA approval, should this product
prove successful it is blue sky potential. Anybody
thinking Mayne will get US distribution rights
because they have 10% of company is barking
up the wrong tree. We have been a failure with
Nextellis. The facts are should this Donesta product
meet expectations Mithra will associate with the highest
bidder and best distribution company suitable in USA.
Simple as that. As long as we conduct extremely high
due diligence and with cash surplus invested to gain
a major shareholding we could be front runners.